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Associations between clinical outcome and patient char-
acteristics, such as tumour gene expression, and inher-
ited variation (single nucleotide polymorphisms) can be
difficult to reproduce between ovarian cancer cohorts.
Sources of variation include the size and composition of
patient cohorts and treatment, which has varied over
time and can vary between countries. We have underta-
ken a review of treatment in patients recruited to the
Australian Ovarian Cancer Study (AOCS) to determine
the primary treatment patterns and levels of consistency
across the cohort. Australian clinical practice guidelines
for the management of women with epithelial ovarian
cancer were published in 2004 [1] and AOCS recruited
women with suspected ovarian, fallopian tube or pri-
mary peritoneal cancer from 2002-2006.
AOCS collected fresh tissue, blood, epidemiological/
dietary questionnaires and clinical follow-up data for
women aged 18-79 diagnosed with invasive (n=1476)
and borderline (n=352) cancer, and material and data
are available for research, by application. Clinical data
was collected through a national research nurse network
at pre-specified intervals: at diagnosis, completion of pri-
mary treatment and then at 6-monthly intervals. At the
end of Feb 2011 primary treatment data was complete
on 99% of eligible cases and the median follow-up time
was 5.1 years.
Most patients with invasive cancer underwent surgery
prior to chemotherapy (n=1190, 82%) and a small pro-
portion had an interval debulk (surgery following ~3
cycles of chemotherapy, 12%) or other procedure
(<10%). The vast majority of women with advanced
stage cancer (FIGO stage II-IV) received chemotherapy
(1116/1167, 96%) and of these, over 99% (1110/1116)
received a platin-based regimen. The most common
regimens were carboplatin/paclitaxel (77%) and carbo-
platin alone (9%), most women (86%) received 6-8 cycles
and 95% of women who received adjuvant chemother-
apy began treatment within 6 weeks of surgery.
In conclusion, the majority of women in AOCS were
treated according to national guidelines, enabling the
selection of cases with uniform treatment for projects
investigating associations of genomic and genetic fea-
tures with clinical outcome.
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